AHRQ drug effectiveness research
Executive Summary
Initial results of the Agency for Healthcare Research & Quality's comparative effectiveness research mandated by the Medicare Modernization Act will be available in October, Center for Outcomes & Evidence Director Jean Slutsky said. The agency is beginning 12 studies on Medicare "priority conditions" using available data (1"The Pink Sheet" Dec. 20, 2004, p. 11)...
You may also be interested in...
AHRQ Drug Effectiveness Comparisons Will Focus On 10 “Priority Conditions”
Prescription drug comparative effectiveness research will proceed for 10 "priority conditions," thanks to $15 mil. provided by the fiscal year 2005 omnibus appropriations bill, the Agency for Healthcare Research & Quality said Dec. 15
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.